Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Duramed Research |
---|---|
Information provided by: | Duramed Research |
ClinicalTrials.gov Identifier: | NCT00117481 |
This is a 3-arm, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of DR-2001 in endometriosis-related symptoms, primarily nonmenstrual pelvic pain, over a 12-week treatment period.
Condition | Intervention | Phase |
---|---|---|
Endometriosis |
Drug: DR-2001a Drug: DR-2001b Other: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate DR-2001 for the Management of Moderate to Severe Endometriosis-Related Nonmenstrual Pelvic Pain |
Estimated Enrollment: | 90 |
Study Start Date: | June 2005 |
Study Completion Date: | December 2007 |
Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: DR-2001a
DR-2001a administered vaginally each month
|
2: Experimental |
Drug: DR-2001b
DR-2001b administered vaginally each month
|
3: Placebo Comparator |
Other: Placebo
Placebo administered vaginally each month
|
This multicenter, double-blind, randomized, placebo-controlled study is designed to evaluate the ability of DR-2001 to produce beneficial changes in endometriosis-related symptoms, primarily nonmenstrual pelvic pain, over a 12-week treatment period. The overall study duration for each patient will be about 20 weeks.
Patients who meet all study entrance criteria will be randomly assigned to one of three treatment groups.
The change in endometriosis-related clinical symptoms will be assessed in two ways: through a combined physician/patient assessment and also with a patient self-assessment. Patients will undergo a gynecologic exam at each study visit.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Chair: | Duramed Protocol Chair | Duramed Research, Inc. |
Responsible Party: | Duramed Research, Inc. ( Duramed Protocol Chair ) |
Study ID Numbers: | DR-DZL-201 |
Study First Received: | June 30, 2005 |
Last Updated: | February 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00117481 |
Health Authority: | United States: Food and Drug Administration |
endometriosis pelvic pain hormonal treatment |
Genital Diseases, Female Signs and Symptoms Pelvic Pain Endometriosis Pain |